Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Drug Pipeline
TERN logo

Merck to Acquire Terns Pharmaceuticals for $53.00 Per Share as Cash Reserves Top $1 Billion

TERN10-KFiling Date: 3/30/2026
Terns Pharmaceuticals, Inc.
Description

What this story covers

Terns Pharmaceuticals is set to be acquired by Merck for $53.00 per share following strong Phase 1/2 data for its CML drug, TERN-701. With $1 billion in cash, Terns is well-positioned for upcoming Phase 3 clinical trials.

Story snapshot

CompanyTerns Pharmaceuticals, Inc.
TickerTERN
VariantStandard detailed
Duration11:23
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001193125-26-131828
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in